Castelli-Haley J - Search Results

1

Burden of a multiple sclerosis relapse: the patient's perspective.

Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Oleen-Burkey M, et al. Patient. 2012;5(1):57-69. doi: 10.2165/11592160-000000000-00000. Patient. 2012. PMID: 22217263

2

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.

Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP. Castelli-Haley J, et al. Adv Ther. 2008 Jul;25(7):658-73. doi: 10.1007/s12325-008-0077-z. Adv Ther. 2008. PMID: 18641926

3

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP. Castelli-Haley J, et al. Adv Ther. 2009 May;26(5):552-62. doi: 10.1007/s12325-009-0028-3. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444392

4

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Castelli-Haley J, et al. J Med Econ. 2010;13(3):464-71. doi: 10.3111/13696998.2010.496650. J Med Econ. 2010. PMID: 20662760 Free article.

5

The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. Oleen-Burkey MA, et al. J Med Econ. 2011;14(6):739-47. doi: 10.3111/13696998.2011.618517. Epub 2011 Sep 13. J Med Econ. 2011. PMID: 21913796 Free article.

6

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Bell C, et al. J Manag Care Pharm. 2007 Apr;13(3):245-61. doi: 10.18553/jmcp.2007.13.3.245. J Manag Care Pharm. 2007. PMID: 17407391 Free PMC article.

7

Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis.

Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Ollendorf DA, et al. J Neurosci Nurs. 2008 Oct;40(5):281-90. doi: 10.1097/01376517-200810000-00006. J Neurosci Nurs. 2008. PMID: 18856249

8

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Earnshaw SR, et al. Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.1007/BF03256144. Appl Health Econ Health Policy. 2009. PMID: 19731967

9

The impact of comorbid depression on adherence to therapy for multiple sclerosis.

Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. Tarrants M, et al. Mult Scler Int. 2011;2011:271321. doi: 10.1155/2011/271321. Epub 2011 Aug 2. Mult Scler Int. 2011. PMID: 22096632 Free PMC article.

10

Cost sharing, benefit design, and adherence: the case of multiple sclerosis.

Dor A, Lage MJ, Tarrants ML, Castelli-Haley J. Dor A, et al. Adv Health Econ Health Serv Res. 2010;22:175-93. doi: 10.1108/s0731-2199(2010)0000022011. Adv Health Econ Health Serv Res. 2010. PMID: 20575233

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters